Anebulo Pharmaceuticals has approved a plan to terminate the registration of its common stock as part of a going-private transaction. The company's board has authorized a reverse stock split with a ratio ranging from 1-for-2,500 to 1-for-7,500. Stockholders will receive $3.50 in cash per pre-split share, representing a 91% premium. This move aims to reduce the number of shareholders and end the company's SEC reporting obligations. Separately, other companies have announced reverse stock splits scheduled for early August 2025, including Anghami with a 1-for-10 split effective August 4, HCTI with a 1-for-249 split effective August 1, and Bollinger Innovations (formerly Mullen Automotive) with a 1-for-250 split also effective August 4.